Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. HIV Drugs Market, by Region, 2018-2027 (USD Billion)
1.2.2. HIV Drugs Market, by Medication Class, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global HIV Drugs Market Definition & Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global HIV Drugs Market Dynamics
3.1. HIV Drugs Market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global HIV Drugs Market: Industry Analysis
4.1. Porters 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porters 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global HIV Drugs Market, by Medication Class
5.1. Market Snapshot
5.2. Global HIV Drugs Market by Medication Class, Performance - Potential Analysis
5.3. Global HIV Drugs Market Estimates & Forecasts by Medication Class, 2017-2027 (USD Billion)
5.4. HIV Drugs Market, Sub Segment Analysis
5.4.1. Multi-class Combination Drugs
5.4.2. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.4.3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.4.4. Protease Inhibitors (P0Is)
5.4.5. Entry Inhibitors
5.4.6. HIV Integrase Strand Transfer Inhibitors
Chapter 6. Global HIV Drugs Market, Regional Analysis
6.1. HIV Drugs Market, Regional Market Snapshot
6.2. North America HIV Drugs Market
6.2.1. U.S. HIV Drugs Market
6.2.1.1. Medication Class breakdown estimates & forecasts, 2017-2027
6.2.2. Canada HIV Drugs Market
6.3. Europe HIV Drugs Market Snapshot
6.3.1. U.K. HIV Drugs Market
6.3.2. Germany HIV Drugs Market
6.3.3. France HIV Drugs Market
6.3.4. Spain HIV Drugs Market
6.3.5. Italy HIV Drugs Market
6.3.6. Rest of Europe HIV Drugs Market
6.4. Asia-Pacific HIV Drugs Market Snapshot
6.4.1. China HIV Drugs Market
6.4.2. India HIV Drugs Market
6.4.3. Japan HIV Drugs Market
6.4.4. Australia HIV Drugs Market
6.4.5. South Korea HIV Drugs Market
6.4.6. Rest of Asia Pacific HIV Drugs Market
6.5. Latin America HIV Drugs Market Snapshot
6.5.1. Brazil HIV Drugs Market
6.5.2. Mexico HIV Drugs Market
6.6. Rest of The World HIV Drugs Market

Chapter 7. Competitive Intelligence
7.1. Top Market Strategies
7.2. Company Profiles
7.2.1. Boehringer Ingelheim International GmbH
7.2.1.1. Key Information
7.2.1.2. Overview
7.2.1.3. Financial (Subject to Data Availability)
7.2.1.4. Industry Summary
7.2.1.5. Recent Developments
7.2.2. Merck & Co., Inc.
7.2.3. ViiV Healthcare
7.2.4. AbbVie
7.2.5. F. Hoffmann-La Roche Ltd.
7.2.6. Teva Pharmaceutical Industries Ltd.
7.2.7. Bristol-Myers Squibb
7.2.8. Gilead Sciences, Inc.
7.2.9. Johnson & Johnson
7.2.10. Cipla Limited
7.2.11. Daiichi Sankyo
7.2.12. Emcure
7.2.13. Hetero Drugs
7.2.14. Mylan
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption